• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-23

  A 2026 study identifies an O-GlcNAc–HUWE1–TfR1 signaling axis that connects trophoblast ferroptosis, iron uptake, and syncytialization defects in preeclampsia. Its combination of O-GlcNAc modification proteomics, mechanistic ubiquitination studies, trophoblast experiments, and mouse validation provides a framework for studying placental stress while highlighting important limits for translation.

• Genetically Engineered Mouse Models of Mesothelioma

  2026-08-22

  Kadariya and colleagues present a protocol-centered framework for modeling malignant mesothelioma with genetically engineered mice carrying germline or conditional Bap1 alterations, with or without asbestos exposure. The review clarifies how these autochthonous models reproduce important genetic, inflammatory, and immune features of human disease and can support therapeutic, chemoprevention, and cancer-interception studies.

• Tacrine hydrochloride hydrate in AD Assays

  2026-08-21

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, provides a practical benchmark for cholinesterase inhibition, cholinergic rescue, and neuroprotection experiments. This guide connects assay-ready preparation with metabolism-aware study design, helping researchers distinguish true biological activity from solvent, stability, or cytotoxicity artifacts.

• Toxoplasma Cyst Wall Regulation: Silva 2023

  2026-08-20

  Toby Silva’s 2023 University of Edinburgh thesis investigates how phosphorylation and the phosphatase PPM3C may regulate Toxoplasma gondii cyst-wall biology through the secreted protein GRA2 and the cyst-wall protein CST1. The work provides a useful experimental framework and preliminary evidence that PPM3C affects CST1 localization, while also revealing important limitations of genetic markers and antibody strategies during bradyzoite differentiation.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-20

  Anlotinib hydrochloride enables a coordinated angiogenesis workflow that connects endothelial migration, tube formation, receptor phosphorylation, and ERK signaling. Its multi-target profile supports mechanism-led cancer research while providing practical options for assay comparison, optimization, and troubleshooting.

• ML365 and NLRP3 in Postoperative Cognitive Impairment

  2026-08-19

  A 2024 Brain Research study found that ML365 pretreatment reduced postoperative cognitive impairment in aged mice after exploratory laparotomy, alongside lower hippocampal NLRP3 inflammasome signaling and oxidative stress. The work offers pharmacological evidence connecting two-pore potassium channel inhibition with postoperative neuroinflammation, while leaving direct target engagement and clinical translation unresolved.

• Dual Enzyme-Responsive Peptides for Cancer Selectivity

  2026-08-19

  The 2026 Biomacromolecules study presents a zwitterionic peptide amphiphile that uses sequential MMP-7-mediated disassembly and cathepsin B-triggered intralysosomal assembly to selectively damage cancer cells. Its reported cancer selectivity index of 64.1 and activity in an HT-29 xenograft model indicate a promising, but still preclinical, strategy for enzyme-gated peptide therapeutics.

• Arsenic, MMP-2/MMP-9, and BBB Cognitive Injury

  2026-08-18

  This study identifies a mechanistic link between chronic sodium arsenite exposure, MMP-2/MMP-9-associated blood-brain barrier disruption, hippocampal neuronal apoptosis, and impaired learning and memory in male mice. Doxycycline hyclate intervention preserved tight-junction features and improved behavioral outcomes, supporting MMP-2 and MMP-9 as experimentally relevant targets in arsenic neurotoxicity.

• KPT-330 (Selinexor) Workflow for CRM1 Studies

  2026-08-17

  Build reproducible CRM1-inhibition assays with KPT-330 (Selinexor), from DMSO stock preparation through viability, apoptosis, ROS, and DNA-damage readouts. The workflow also translates recent DLBCL combination findings into practical platinum-sensitivity experiments while separating literature evidence from starting-point optimization.

• RIPA Lysis Buffer Strong: Practical Workflow

  2026-08-17

  RIPA Lysis Buffer (Strong, without inhibitors) provides detergent-based extraction for animal cells and tissues when robust protein solubilization and customized inhibitor selection are required. It is appropriate for Western blotting, immunoprecipitation, ELISA, and protein kinase workflows, but should be evaluated carefully when native protein complexes, enzyme activity, or inhibitor-free conditions are essential.

• Nadolol (SQ-11725) Assay Workflow Guide

  2026-08-16

  Build more reliable cardiovascular assays with Nadolol (SQ-11725) by separating beta-adrenergic blockade from transporter-dependent exposure and assay artifacts. This practical workflow covers cell signaling, PK sampling, tissue-distribution logic, and troubleshooting for hypertension research, angina pectoris studies, and vascular headache research.

• ATM Inhibition, Macropinocytosis, and Metabolic Adaptation

  2026-08-15

  The reference study shows that suppressing ATM does more than weaken DNA damage signaling: it induces macropinocytosis, increases nutrient acquisition, and supports cancer-cell survival under nutrient limitation. Its combination of cell-based uptake assays, amino-acid rescue, metabolomics, and tumor models identifies branched-chain amino-acid dependence as a potential metabolic vulnerability of ATM-inhibited cancers.

• Macrocyclic Hedgehog Inhibitors: SAR and Mechanism

  2026-08-14

  Dockendorff and colleagues used a modular build-couple-pair synthesis strategy to optimize macrocyclic Hedgehog pathway inhibitors and identify analogues with substantially improved cellular activity. The study also showed, through Ptch knockout and agonist-competition experiments, that selected analogues act as Smoothened antagonists rather than merely reproducing the behavior of the original robotnikinin scaffold.

• ABT-199 and the Logic of Mitochondrial Apoptosis

  2026-08-14

  ABT-199 (GDC-0199; Venetoclax) provides a precise way to interrogate BCL-2 dependence, while recent work on RNA Pol II degradation reframes apoptosis as an actively sensed, mitochondria-directed response. This article translates those insights into a practical strategy for hematologic malignancy research, assay design, and biomarker development.

• DiI (DiIC18(3)) Plasma Membrane Probe

  2026-08-13

  DiI (DiIC18(3)) is a water-insoluble, lipophilic fluorescent dye for orange-red plasma membrane labeling in live or fixed cells and tissues. It is appropriate for membrane tracing, migration, fusion, adhesion, and lipoprotein workflows, but not for aqueous-only protocols or experiments requiring exclusive intracellular organelle staining.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page